KILITCH DRUGS (INDIA) Q3 FY25 Results
KILITCH DRUGS (INDIA) has released its financial results for the Q3 quarter of Financial Year 24-2025. Here's a comprehensive breakdown of the company's performance:
Revenue Analysis
- Current Quarter Revenue: Rs. 56.17 Cr
- Quarter-on-Quarter (QoQ) Change: 18.31% (Previous Quarter: Rs. 47.47 Cr )
- Year-on-Year (YoY) Change: 76.65% (Same Quarter Last Year: Rs. 31.79 Cr )
Profitability Metrics
- Net Profit: Rs. 5.61 Cr
- QoQ Profit Change: -34.80% (Previous Quarter: Rs. 8.61 Cr )
- YoY Profit Change: 222.39% (Same Quarter Last Year: Rs. 1.74 Cr )
Shareholder Returns
- Earnings Per Share (EPS): Rs. 3.71
- QoQ EPS Change: -30.78% (Previous Quarter: Rs. 5.36)
- YoY EPS Change: 100.54% (Same Quarter Last Year: Rs. 1.85)
Performance Summary
Exceptional
KILITCH DRUGS (INDIA) grew exceptionally well in both sales and profits, showing strength in all areas. This indicates a very healthy business.
This analysis provides a snapshot of KILITCH DRUGS (INDIA)'s financial performance. Investors and analysts should consider these results in the context of broader market trends and the company's long-term strategy.
Disclaimer:
This information is for informational purposes only. Please reverify all details from official sources before making any financial decisions. The accuracy and completeness of this data cannot be guaranteed.